Genetic PredispositionNCT04920513
Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.
An observational study of Genetic Predisposition, run by King Hussein Cancer Center at 1 site in Jordan.
Trial summary
The investigators aim to study the pattern and frequency of pathogenic variants among ALL newly diagnosed cancer patients in a genetically distinct population. Additionally, the investigators will study the uptake rate of "cascade family screening", frequency of pathogenic variants and barriers against testing. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Genetic Predisposition
- How many people
- 3,000 participants
- Where
- 1 siteJordan
- Study dates
- 1 May 2021to 1 Feb 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All consecutive patients who fulfill the inclusion/exclusion criteria and are diagnosedat KHCC will be invited. A total of 3000 patients are estimated to participate
Who may be able to join
- Adult patient, age ≥ 18 years at time of cancer diagnosis
- Pathology proven diagnosis of cancer; any site, any stage (prior history of cancer is allowed)
- Jordanian nationality
- Willingness to participate
- Signed consent form
Who cannot join
- Major psychiatric disorder (defined as: patients followed by a psychiatrist and on antipsychotic medications)
- Non-Jordanian
- Patients with Leukemia, Lymphoma and Myeloma
Trial locations and contacts
1 site in 1 country.
About this study
The investigators aim to study the pattern and frequency of pathogenic variants among ALL newly diagnosed cancer patients in a genetically distinct population.
Additionally, the investigators will study the uptake rate of "cascade family screening", frequency of pathogenic variants and barriers against testing.
- Conditions
- Genetic Predisposition
- Keywords
- Genetics
- Medical subject headings
- Genetic Predisposition to Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of pathogenic or likely pathogenic germline variants among newly diagnosed cancer patients tested by universal multigene panel testing
Measured: 2021-2023
Number of participants with variants of uncertain significance (VUS) as assessed by universal multigene panel testing
Measured: 2021-2023
To determine the reasons/ Barriers for refusal of genetic cascade testing among newly diagnosed cancer patients.
Measured: 2021-2023
Secondary outcomes (4)
Rate of cascade of family member testing of the participants with positive pathogenic mutation
The family of tested patients with pathogenic mutations will be offered the genetic testing
Measured: 2021-2023
Prevalence of pathogenic or likely pathogenic mutations among tested family members of the participants with pathogenic mutations using the universal multigene panel
Measured: 2021-2023
Prevalence of variants of uncertain significance (VUS) among tested family members of participants with pathogenic mutations as assessed by universal multigene panel testing
Measured: 2021-2023
To determine the reasons/ Barriers for refusal of genetic cascade testing among family members of tested patients with pathogenic mutation
Measured: 2021-2023
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2021
- Study start1 May 2021
- Primary completion1 Feb 2025
- Study completion1 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Genetic PredispositionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- King Hussein Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hikmat Abdel-Razeq, King Hussein Cancer Center
- Investigators
- Hikmat Abdel-Razeq, Principal investigator, King Hussein Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04920513
- Sponsor's protocol ID
- 21 KHCC 27
- Status last verified
- Mar 2025
- First submitted
- 16 May 2021
- Last updated
- 19 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.
- ClinicalTrials.gov ID
- NCT04920513
- Acronym / sponsor ID
- 21 KHCC 27
- Conditions
- Genetic Predisposition
- Keywords
- Genetics
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,000 participants (actual)
- Lead sponsor
- King Hussein Cancer CenterUniversity, hospital or other
- Study start
- 1 May 2021 (actual)
- Primary completion
- 1 Feb 2025 (actual)
- Study completion
- 1 Feb 2025 (actual)
- First posted
- 10 Jun 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators aim to study the pattern and frequency of pathogenic variants among ALL newly diagnosed cancer patients in a genetically distinct population.
Additionally, the investigators will study the uptake rate of "cascade family screening", frequency of pathogenic variants and barriers against testing.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All consecutive patients who fulfill the inclusion/exclusion criteria and are diagnosedat KHCC will be invited. A total of 3000 patients are estimated to participate
Key inclusion criteria (5 listed)
- Adult patient, age ≥ 18 years at time of cancer diagnosis
- Pathology proven diagnosis of cancer; any site, any stage (prior history of cancer is allowed)
- Jordanian nationality
- Willingness to participate
- Signed consent form
Key exclusion criteria (3 listed)
- Major psychiatric disorder (defined as: patients followed by a psychiatrist and on antipsychotic medications)
- Non-Jordanian
- Patients with Leukemia, Lymphoma and Myeloma
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence of pathogenic or likely pathogenic germline variants among newly diagnosed cancer patients tested by universal multigene panel testing
Time frame: 2021-2023
Number of participants with variants of uncertain significance (VUS) as assessed by universal multigene panel testing
Time frame: 2021-2023
To determine the reasons/ Barriers for refusal of genetic cascade testing among newly diagnosed cancer patients.
Time frame: 2021-2023
4 secondary outcomes
Rate of cascade of family member testing of the participants with positive pathogenic mutation
Time frame: 2021-2023
Prevalence of pathogenic or likely pathogenic mutations among tested family members of the participants with pathogenic mutations using the universal multigene panel
Time frame: 2021-2023
Prevalence of variants of uncertain significance (VUS) among tested family members of participants with pathogenic mutations as assessed by universal multigene panel testing
Time frame: 2021-2023
To determine the reasons/ Barriers for refusal of genetic cascade testing among family members of tested patients with pathogenic mutation
Time frame: 2021-2023
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2025.
Related trials for Genetic Predisposition
RecruitingObservational study
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
Renal Tumor Histology, Cutaneous Leiomyoma
RecruitingObservational study
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
Kidney Neoplasms, Kidney Cancer
RecruitingObservational study
Vascular Disease Discovery Protocol
Vascular Dysfunction, Genetic Mutations
RecruitingObservational study
Precision-Based Genomics in Prostate Cancer
Prostate Cancer
RecruitingObservational study
Rare Tumors and Cancer Predisposition in Individuals and Families
Cancer, Hereditary Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hikmat Abdel-Razeq principal investigator
King Hussein Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Genetic Predisposition, run by King Hussein Cancer Center at 1 site in Jordan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Jordan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of pathogenic or likely pathogenic germline variants among newly diagnosed cancer patients tested by universal multigene panel testing (time frame: 2021-2023). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2025.